Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Abstracts

Abstracts Squibb, Beigene, Aveo, Taiho, Pfizer, Boehringer Ingelheim. G. Consultant; PLENARY AstraZeneca, Roche, Eli Lilly, Merck Serono, Eisai, Bristol-Myers Squibb, Beigene, Aveo, Taiho, Pfizer, Boehringer Ingelheim. D. Massey: A. Employee; Boehringer Ingelheim Limited UK. V. Zazulina: A. Employee; Boehringer Ingelheim Limited UK. M. Shahidi: A. Employee; Boehringer Ingelheim LUX-Lung 3: A Randomized, Open-Label, Phase III Study of Limited UK. J. Yang: F. Honoraria; Boehringer Ingelheim. G. Consultant; Afatinib vs Pemetrexed and Cisplatin as First-Line Treatment Boehringer Ingelheim. for Patients with Advanced Adenocarcinoma of the Lung Harboring EGFR-Activating Mutations (Subgroup Analysis) 1 2 3 4 5 6 L. Sequist , M. Schuler , N. Yamamoto , K. O’Byrne , V. Hirsh , T. Mok , 7 7 7 8 1 D. Massey , V. Zazulina , M. Shahidi , J. Yang , Massachusetts General Dacomitinib (D) Versus Erlotinib (E) in Patients (pt) with Hospital, Boston, MA, West German Cancer Center, University Duisburg- EGFR-mutated (mu) Advanced Non-small Cell Lung Cancer 3 4 Essen, Essen, Germany, Shizuoka Cancer Center, Shizuoka, Japan, St. 5 (NSCLC): Analyses from a Randomized, Phase 2 Trial James’ Hospital, Dublin, Ireland, McGill University, Montreal, QC, Canada, 1 2 3 4 5 6 6 7 S. Ramalingam , F. Blackhall http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Loading next page...
 
/lp/wolters-kluwer-health/abstracts-PWAdT2d8Qx
ISSN
1556-0864

Abstract

Squibb, Beigene, Aveo, Taiho, Pfizer, Boehringer Ingelheim. G. Consultant; PLENARY AstraZeneca, Roche, Eli Lilly, Merck Serono, Eisai, Bristol-Myers Squibb, Beigene, Aveo, Taiho, Pfizer, Boehringer Ingelheim. D. Massey: A. Employee; Boehringer Ingelheim Limited UK. V. Zazulina: A. Employee; Boehringer Ingelheim Limited UK. M. Shahidi: A. Employee; Boehringer Ingelheim LUX-Lung 3: A Randomized, Open-Label, Phase III Study of Limited UK. J. Yang: F. Honoraria; Boehringer Ingelheim. G. Consultant; Afatinib vs Pemetrexed and Cisplatin as First-Line Treatment Boehringer Ingelheim. for Patients with Advanced Adenocarcinoma of the Lung Harboring EGFR-Activating Mutations (Subgroup Analysis) 1 2 3 4 5 6 L. Sequist , M. Schuler , N. Yamamoto , K. O’Byrne , V. Hirsh , T. Mok , 7 7 7 8 1 D. Massey , V. Zazulina , M. Shahidi , J. Yang , Massachusetts General Dacomitinib (D) Versus Erlotinib (E) in Patients (pt) with Hospital, Boston, MA, West German Cancer Center, University Duisburg- EGFR-mutated (mu) Advanced Non-small Cell Lung Cancer 3 4 Essen, Essen, Germany, Shizuoka Cancer Center, Shizuoka, Japan, St. 5 (NSCLC): Analyses from a Randomized, Phase 2 Trial James’ Hospital, Dublin, Ireland, McGill University, Montreal, QC, Canada, 1 2 3 4 5 6 6 7 S. Ramalingam , F. Blackhall

Journal

Journal of Thoracic OncologyWolters Kluwer Health

Published: Sep 1, 2012

There are no references for this article.